Download PDF
Thromb Haemost 2003; 90(03): 439-445
DOI: 10.1160/TH03-01-0035
Blood Coagulation, Fibrinolysis and Cellular Haemostasis
Schattauer GmbH

Frequency of the TAFI –438 G/A and factor XIIIA Val34Leu polymorphisms in patients with objectively proven pulmonary embolism

Majida Zidane
1   Department of General Internal Medicine, Department of Hematology
,
Marieke C. H. de Visser
2   Hemostasis and Thrombosis Research Center, Department of Hematology
,
Marije ten Wolde
4   Department of Vascular Medicine, Academic Medical Center, Amsterdam, The Netherlands
,
Hans L.Vos
2   Hemostasis and Thrombosis Research Center, Department of Hematology
,
Wouter de Monyé
3   Department of Radiology, Leiden University Medical Center, Leiden, The Netherlands
,
Rogier M. Bertina
2   Hemostasis and Thrombosis Research Center, Department of Hematology
,
Menno V. Huisman
1   Department of General Internal Medicine, Department of Hematology
,
the Antelope study group › Author Affiliations
Further Information

Publication History

Received 17 January 2003

Accepted after resubmission 28 May 2003

Publication Date:
05 December 2017 (online)

    Permissions and Reprints

Summary

Deep vein thrombosis (DVT) and pulmonary embolism (PE) are considered to be two forms of the same disease, however it is not fully understood what determines their clinical presentation.

Proteins encoded by the FXIIIA and TAFI genes are involved in stabilizing the fibrin clot and in making it more lysis resistant. The FXIIIA 34Leu and TAFI –438A alleles might protect against DVT. Information on such an association with PE is either contradictory or missing. We hypothesized that both polymorphisms might influence the formation and fate of emboli and accordingly the risk of PE. We determined the frequencies of both polymorphisms in patients with objectively demonstrated PE.

The frequency of FXIIIA Leu34Leu in PE patients and non-PE patients was 4.5% and 8.8%, [OR 0.5 (95% CI: 0.1 to 1.9)], respectively. For –438 A/A TAFI genotype the frequency was 1.5% and 8.1% [OR 0.1 (95% CI: 0.02 to 1.1)], respectively.

Keywords

Pulmonary embolism - thrombin activatable fibrinolysis inhibitor (TAFI) / carboxypeptidases - Factor XIII / transglutaminases
 

  • References

  • 1 Gaffney PJ, Edgell TA, Whitton CM. The haemostatic balance – Astrup revisited. Haemostasis 1999; 29 (01) 58-71.
    PubMedGoogle Scholar
  • 2 Bertina RM. Molecular risk factors for thrombosis. Thromb Haemost 1999; 82 (02) 601-9.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 3 Bertina RM, Koeleman BP, Koster T. et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369 6475 64-7.
    CrossrefPubMedGoogle Scholar
  • 4 Ridker PM, Miletich JP, Hennekens CH. et al. Ethnic distribution of factor V Leiden in 4047 men and women. Implications for venous thromboembolism screening. JAMA 1997; 277 (16) 1305-7.
    CrossrefPubMedGoogle Scholar
  • 5 Rees DC, Cox M, Clegg JB. World distribution of factor V Leiden. Lancet 1995; 346 8983 1133-4.
    CrossrefPubMedGoogle Scholar
  • 6 Poort SR, Rosendaal FR, Reitsma PH. et al. A common genetic variation in the 3’-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996; 88 (10) 3698-703.
    PubMedGoogle Scholar
  • 7 Balogh I, Szoke G, Karpati L. et al. Val34Leu polymorphism of plasma factor XIII: biochemistry and epidemiology in familial thrombophilia. Blood 2000; 96 (07) 2479-86.
    PubMedGoogle Scholar
  • 8 Corral J, Gonzalez-Conejero R, Iniesta JA. et al. The FXIII Val34Leu polymorphism in venous and arterial thromboembolism. Haematologica 2000; 85 (03) 293-7.
    PubMedGoogle Scholar
  • 9 Franco RF, Reitsma PH, Lourenco D. et al. Factor XIII Val34Leu is a genetic factor involved in the etiology of venous thrombosis. Thromb Haemost 1999; 81 (05) 676-9.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 10 Catto AJ, Kohler HP, Coore J. et al. Association of a common polymorphism in the factor XIII gene with venous thrombosis. Blood 1999; 93 (03) 906-8.
    PubMedGoogle Scholar
  • 11 Alhenc-Gelas M, Reny JL, Aubry ML. et al. The FXIII Val 34 Leu mutation and the risk of venous thrombosis. [letter] . Thromb Haemost 2000; 84 (06) 1117-8.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 12 van Hylckama Vlieg A, Komanasin N, Ariëns RAS. et al. Factor XIII Val34Leu polymorphism, factor XIII antigen levels and activity and the risk of deep venous thrombosis. Br J Haematol 2002; 119 (01) 169-75.
    CrossrefPubMedGoogle Scholar
  • 13 Franco RF, Fagundes MG, Meijers JC. et al. Identification of polymorphisms in the 5’-untranslated region of the TAFI gene: relationship with plasma TAFI levels and risk of venous thrombosis. Haematologica 2001; 86 (05) 510-7.
    PubMedGoogle Scholar
  • 14 Muszbek L, Yee VC, Hevessy Z. Blood coagulation factor XIII: structure and function. Thromb Res 1999; 94 (05) 271-305.
    CrossrefPubMedGoogle Scholar
  • 15 Kohler HP, Ariëns RA, Whitaker P. et al. A common coding polymorphism in the FXIII A-subunit gene (FXIIIVal34Leu) affects cross-linking activity. [letter]. Thromb Haemost 1998; 80 (04) 704.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 16 Wartiovaara U, Mikkola H, Szoke G. et al. Effect of Val34Leu polymorphism on the activation of the coagulation factor XIII-A. Thromb Haemost 2000; 84 (04) 595-600.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 17 Kangsadalampai S, Board PG. The Val34Leu polymorphism in the A subunit of coagulation factor XIII contributes to the large normal range in activity and demonstrates that the activation peptide plays a role in catalytic activity. Blood 1998; 92 (08) 2766-70.
    PubMedGoogle Scholar
  • 18 Trumbo TA, Maurer MC. Examining thrombin hydrolysis of the factor XIII activation peptide segment leads to a proposal for explaining the cardioprotective effects observed with the factor XIII V34L mutation. J Biol Chem 2000; 275 (27) 20627-31.
    CrossrefPubMedGoogle Scholar
  • 19 Ariëns RA, Philippou H, Nagaswami C. et al. The factor XIII V34L polymorphism accelerates thrombin activation of factor XIII and affects cross-linked fibrin structure. Blood 2000; 96 (03) 988-95.
    PubMedGoogle Scholar
  • 20 Atwa AAA, Grant PJ, Ariëns RAS.. Effect of the FXIII Val34Leu polymorphism on the interaction between platelets and cross-linked fibrin. Thromb Haemost (suppl.). 2001 (abstract)
    PubMedGoogle Scholar
  • 21 Ariëns RAS, Collet PJ, Grant PJ. et al. Effect of the FXIII Val34Leu polymorphism on the structure and elastic properties of fibrin clots and on fibrinolysis rates. Thromb Haemost (suppl.). 2001 (abstract)
    PubMedGoogle Scholar
  • 22 Ehrenforth S, Zwinge B, Krause M. et al. Association between the Val34Leu polymorphism of factor XIII gene and pulmonary embolism. Thromb Haemost (suppl.). 2001 (abstract)
    PubMedGoogle Scholar
  • 23 Bajzar L. Thrombin activatable fibrinolysis inhibitor and an antifibrinolytic pathway. Arterioscler Thromb Vasc Biol 2000; 20 (12) 2511-8.
    CrossrefPubMedGoogle Scholar
  • 24 van Tilburg NH, Rosendaal FR, Bertina RM. Thrombin activatable fibrinolysis inhibitor and the risk for deep vein thrombosis. Blood 2000; 95 (09) 2855-9.
    PubMedGoogle Scholar
  • 25 Henry M, Aubert H, Morange PE. et al. Identification of polymorphisms in the promoter and the 3’ region of the TAFI gene: evidence that plasma TAFI antigen levels are strongly genetically controlled. Blood 2001; 97 (07) 2053-8.
    CrossrefPubMedGoogle Scholar
  • 26 Brouwers GJ, Vos HL, Leebeek FW. et al. A novel, possibly functional, single nucleotide polymorphism in the coding region of the thrombin-activatable fibrinolysis inhibitor (TAFI) gene is also associated with TAFI levels [letter]. Blood 2001; 98 (06) 1992-3.
    CrossrefPubMedGoogle Scholar
  • 27 de Monyé W, van Strijen MJ, Huisman MV. et al. Suspected pulmonary embolism: prevalence and anatomic distribution in 487 consecutive patients. Advances in New Technologies Evaluating the Localisation of Pulmonary Embolism (ANTELOPE) Group. Radiology 2000; 215 (01) 184-8.
    CrossrefPubMedGoogle Scholar
  • 28 Lensing AW, van Beek EJ, Demers C. et al. Ventilation-perfusion lung scanning and the diagnosis of pulmonary embolism: improvement of observer agreement by the use of a lung segment reference chart. Thromb Haemost 1992; 68 (03) 245-9.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 29 Hull RD, Hirsh J, Carter CJ. et al. Diagnostic value of ventilation-perfusion lung scanning in patients with suspected pulmonary embolism. Chest 1985; 88 (06) 819-28.
    CrossrefPubMedGoogle Scholar
  • 30 Woolf B. On estimating the relation between group and disease. Am J Hum Genet 1955; 19: 251-3.
    PubMedGoogle Scholar
  • 31 Huisman MV, Büller HR, ten Cate JW. et al. Unexpected high prevalence of silent pulmonary embolism in patients with deep venous thrombosis. Chest 1989; 95 (03) 498-502.
    CrossrefPubMedGoogle Scholar
  • 32 Nielsen HK, Husted SE, Krusell LR. et al. Silent pulmonary embolism in patients with deep venous thrombosis. Incidence and fate in a randomized, controlled trial of anticoagulation versus no anticoagulation. J Intern Med 1994; 235 (05) 457-61.
    CrossrefPubMedGoogle Scholar
  • 33 Monreal M, Rey-Joly BC, Ruiz MJ. et al. Asymptomatic pulmonary embolism in patients with deep vein thrombosis. Is it useful to take a lung scan to rule out this condition?. J Cardiovasc Surg (Torino) 1989; 30 (01) 104-7.
    PubMedGoogle Scholar